Lacosamide Hameln (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyper‑excitability. It also binds to CRMP‑2, a protein involved in neuronal development, which may further contribute to its seizure‑suppressing properties.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s age, weight, renal function, and overall treatment plan. Healthcare providers tailor the regimen to achieve optimal seizure control while minimizing adverse effects.

Safety data for Lacosamide in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and necessary import documentation.

Lacosamide differs from many traditional sodium‑channel blockers such as carbamazepine by selectively enhancing slow inactivation rather than blocking fast inactivation. This mechanism may result in fewer drug‑interaction issues and a distinct side‑effect profile, making it a valuable add‑on option for patients who do not achieve control with other agents.

Lacosamide Hameln should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Do not freeze the solution. Before administration, inspect the vial for particulate matter and ensure the solution is clear.

The product is supplied as an intravenous solution and is administered by slow infusion into a peripheral or central vein. The infusion rate and total daily dose are set by the prescriber, who may adjust based on clinical response and tolerability.

Serious adverse events include cardiac arrhythmias, especially PR‑interval prolongation, and psychiatric effects such as suicidal thoughts. Rare but severe skin reactions like Stevens‑Johnson syndrome may also occur. Patients should be monitored closely for any new cardiac or psychiatric symptoms.

Lacosamide is contraindicated in patients with known hypersensitivity to the drug or any of its excipients. Caution is advised for individuals with significant cardiac conduction disorders, severe renal or hepatic impairment, and those taking other strong sodium‑channel blockers unless supervised by a specialist.